Elevated Graft-versus-Host Disease Risk Among International Stem Cell Transplant Recipients: A Pilot Study from the UAE
Authors:
- Syed NaveedSyed Naveed
- Afrooz ImranaAIAfrooz Imrana
- Mir Ahmed FarooqMFMir Ahmed Farooq
- Khan Ali AzmatKAKhan Ali Azmat
- Abdulla J.M.H NadaANAbdulla J.M.H Nada
- Hussain ShakirHSHussain Shakir
- Chandani Uttam AshokCAChandani Uttam Ashok
- Hasan AmeraHAHasan Amera
- Samad Abdel HaninSHSamad Abdel Hanin
- ElGhazali GehadEGElGhazali Gehad
- Hashmi ShahrukhHSHashmi Shahrukh
Preprint
- 31 July 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Patients from regions without stem cell transplant (SCT) facilities often seek treatment abroad and return home for post-transplant care. While extensive data exists on GVHD and its risk factors, the prevalence of GVHD in international SCT patients returning to countries without transplant facilities, where multiple factors compromise post-transplant care, is not well documented. We screened 149 transplant recipients and analyzed data from 91 who received transplants abroad and were followed at our center from January 2019 to December 2022. This observational study used data from electronic medical records (EMR) and employed descriptive statistics, inferential tests, and relative risk calculations with forest plots to analyze GVHD prevalence and key risk factors. Of the recipients, 31.8% were residents from nine countries living in the UAE, and 67.2% were UAE citizens. Adults comprised 48.3% of the recipients, and 51.7% were pediatric. Hematological malignancies were the most common indication (49%), primarily in adults. Siblings were the majority of donors (52.6%), followed by related donors (23.09%), and unrelated donors (8.9%). Most (69.2%) received HLA-identical transplants followed by 21.9% who received haploidentical. Among adults, 62.2% developed GVHD, compared to 26% of pediatric patients. Recipients with related HLA-identical donors had a 50% GVHD prevalence, while those with unrelated identical donors had 71%. The overall GVHD prevalence was 50% among the 87.9% who received allogeneic SCTs. Despite favorable factors, GVHD prevalence remains high. Larger multicenter studies are needed to identify and assess the impact of contributing factors.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Current Use of and Trends in Hematopoietic Cell Transplantation in the United StatesTransplantation and Cellular Therapy, 2020
- Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2015
- Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium StudyTransplantation and Cellular Therapy, 2013
- Graft versus host disease: clinical evaluation, diagnosis and managementGraefe's Archive for Clinical and Experimental Ophthalmology, 2013
- Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow TransplantsTransplantation and Cellular Therapy, 2009
- 11: Risk Factor Analysis for the Development of Restrictive and Obstructive Pulmonary Function Changes After Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2008
- T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2006
- Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2006
- Chronic Graft-vs-Host DiseaseJAMA, 2003
- Cyclosporine and the thymus: Influence of irradiation and age on thymic immunopathology and recoveryCellular Immunology, 1987